Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Transcriptional control of viral gene therapy by cisplatin
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):403-410. https://doi.org/10.1172/JCI15548.
View: Text | PDF
Article Genetics

Transcriptional control of viral gene therapy by cisplatin

  • Text
  • PDF
Abstract

Research Article

Authors

James O. Park, Carlos A. Lopez, Vinay K. Gupta, Charles K. Brown, Helena J. Mauceri, Thomas E. Darga, Abdullah Manan, Samuel Hellman, Mitchell C. Posner, Donald W. Kufe, Ralph R. Weichselbaum

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
In vitro reporter assays. Luciferase reporter constructs were used to ev...
In vitro reporter assays. Luciferase reporter constructs were used to evaluate induction of the Egr1 promoter by IR or cisplatin. Minimal LA was detectable following transfection with either the pGL3 basic (negative control) or the pGL3 660 plasmid (minimal Egr1 promoter) constructs. (a) In Seg-1 cells transfected with pGL3 425, a 2.4-fold increase (P = 0.005) in relative LA was observed following exposure to IR (20 Gy), and a 2.0-fold increase (P = 0.005) was seen following exposure to cisplatin (50 μM). (b) In PROb cells transfected with pGL3 425, there was a 4.2-fold increase (P = 0.004) in relative LA following exposure to IR (20 Gy), and a 3.6-fold increase (P = 0.01) following exposure to cisplatin (50 μM). Data are reported as mean ± SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts